- active not recruitingPHASE2
Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
This study is checking a new medicine called AOC 1020 for people with Facioscapulohumeral Muscular Dystrophy (FSHD). It's for people who were in an earlier study of this medicine. The aim is to see if it's safe and helps over a longer time.
United States · Canada · United Kingdom - enrolling by invitationNA
The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.
This study looks at how walking aids and training can help people with certain muscle and nerve conditions fall less often. It aims to improve their safety and daily life by finding the best ways to use these aids.
Germany - recruitingPHASE1, PHASE2
Study of ARO-DUX4 in Adult and Adolescent Patients With Facioscapulohumeral Muscular Dystrophy Type 1
This study is looking at a new medicine called ARO-DUX4 for people with a muscle condition called facioscapulohumeral muscular dystrophy type 1 (FSHD1). It will check if the medicine is safe and how it works in the body.
Australia · Canada · Germany - recruitingPHASE3
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
This study is testing a new medicine called del-brax for people with Facioscapulohumeral Muscular Dystrophy (FSHD). Researchers want to see if it's safe and effective in improving or slowing down the condition. It involves receiving treatment every six weeks for over a year.
United States · Canada · Denmark